Eastern Hub, Bowel Cancer Screening Programme, A Floor West Block, QMC Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Division of Cancer and Stem Cells, School of Medicine, Room W/D3, D Floor, West Block, Queen's Medical Centre, Nottingham, UK.
Clin Chem Lab Med. 2020 Oct 29;59(4):721-728. doi: 10.1515/cclm-2020-1170. Print 2021 Mar 26.
Currently, NICE recommends the use of faecal immunochemical test (FIT) at faecal haemoglobin concentrations (f-Hb) of 10 μg Hb/g faeces to stratify for colorectal cancer (CRC) risk in symptomatic populations. This f-Hb cut-off is advised across all analysers, despite the fact that a direct comparison of analyser performance, in a clinical setting, has not been performed.
Two specimen collection devices (OC-Sensor, OC-S; HM-JACKarc, HM-J) were sent to 914 consecutive individuals referred for follow up due to their increased risk of CRC. Agreement of f-Hb around cut-offs of 4, 10 and 150 µg Hb/g faeces and CRC detection rates were assessed. Two OC-S devices were sent to a further 114 individuals, for within test comparisons.
A total of 732 (80.1%) individuals correctly completed and returned two different FIT devices, with 38 (5.2%) CRCs detected. Median f-Hb for individuals diagnosed with and without CRC were 258.5 and 1.8 µg Hb/g faeces for OC-S and 318.1 and 1.0 µg Hb/g faeces for HM-J respectively. Correlation of f-Hb results between OC-S/HM-J over the full range was rho=0.74, p<0.001. Using a f-Hb of 4 µg Hb/g faeces for both tests found an agreement of 88.1%, at 10 µg Hb/g faeces 91.7% and at 150 µg Hb/g faeces 96.3%. A total of 114 individuals completed and returned two OC-S devices; correlation across the full range was rho=0.98, p<0.001.
We found large variations in f-Hb when different FIT devices were used, but a smaller variation when the same FIT device was used. Our data suggest that analyser-specific f-Hb cut-offs are applied with regard to clinical decision making, especially at lower f-Hb.
目前,NICE 建议在粪便血红蛋白浓度(f-Hb)为 10μg Hb/g 粪便时使用粪便免疫化学测试(FIT)对有症状人群进行结直肠癌(CRC)风险分层。尽管尚未在临床环境中直接比较分析器的性能,但建议在所有分析器上使用此 f-Hb 截止值。
将两种标本采集装置(OC-Sensor,OC-S;HM-JACKarc,HM-J)发送给 914 名因 CRC 风险增加而接受随访的连续个体。评估了 f-Hb 在 4、10 和 150μg Hb/g 粪便的截止值周围的一致性和 CRC 检出率。将两个 OC-S 装置发送给另外 114 名个体进行内部测试比较。
共有 732 名(80.1%)个体正确完成并返回了两个不同的 FIT 装置,其中检出 38 例(5.2%)CRC。诊断为 CRC 和无 CRC 的个体的中位 f-Hb 分别为 OC-S 的 258.5 和 1.8μg Hb/g 粪便,HM-J 的 318.1 和 1.0μg Hb/g 粪便。OC-S/HM-J 之间在全范围内的 f-Hb 结果相关性为 rho=0.74,p<0.001。对于两种测试,使用 4μg Hb/g 粪便的 f-Hb 发现一致性为 88.1%,使用 10μg Hb/g 粪便的 f-Hb 发现一致性为 91.7%,使用 150μg Hb/g 粪便的 f-Hb 发现一致性为 96.3%。共有 114 名个体完成并返回了两个 OC-S 装置;在全范围内的相关性为 rho=0.98,p<0.001。
我们发现使用不同的 FIT 装置时 f-Hb 有很大差异,但使用相同的 FIT 装置时差异较小。我们的数据表明,特别是在 f-Hb 较低的情况下,分析器特异性 f-Hb 截止值应用于临床决策。